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Key issues at a glance 
Use of GHB, also commonly referred to as 'liquid
ecstasy', surfaced on the recreational nightlife scene
in some parts of Europe, the USA and Australia
during the 1990s. It is usually consumed in
recreational nightlife settings, where it is taken orally
in liquid form for sought-after effects that are close to
alcohol. More recently, there have been reports of
direct consumption of the precursor chemical,
gamma-butyrolactone (GBL) which is rapidly
converted into GHB in the body.
Use of GHB/GBL is, generally, low in the EU but
there is evidence of some sub-populations, settings
and geographical areas where it is commonly used,
such as in gay nightclubs. Among 15–16 year old
school students lifetime prevalence is between 0.5 %
and 1.4 % in 12 of the EU countries. Surveys
conducted in dance music settings report higher
prevalence estimates for ever in lifetime use of GHB
that range from 3 % to 19 % but prevalence drops
to less than 3 % in all estimates for last month use.
Little is known about use of GHB in private settings
for purposes of recreation, bodybuilding and self
medication.
In March 2001, GHB (shown as gamma-
hydroxybutyric acid) was added to Schedule IV of
the 1971 UN Convention on Psychotropic
Substances. Therefore, all EU Member States were
bound to control it under their legislation addressing
psychotropic substances. The new controls rapidly
curtailed the previously open sale of GHB. They may
also help to explain the emergent use of GBL, which
does not fall under the controls of the international
drug control convention.
GHB has a steep dose-response curve where even a
small increase in dose can cause serious toxic
effects, including impaired consciousness and coma.
Combined use of alcohol or other psychoactive
substances, both depressants and stimulants, may
intensify the toxic effects of GHB. With the increased
direct consumption of GHB's precursors, additional
health challenges may arise.
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Concerns are increasing about the use of GHB
precursor chemicals, gamma-butyrolactone (GBL)
and 1,4-butanediol (1,4-BD), that are rapidly
converted to GHB when ingested. Furthermore, GHB
can be easily manufactured from GBL and 1,4-BD,
which are widely used in the chemical industry and
commercially available. Some Member States (Italy,
Latvia, Sweden) have chosen to control one or both
precursors under drug control or equivalent
legislation. The European Community and the
Member States have taken additional voluntary
measures to prevent their diversion.
The ease with which GBL can be acquired allows
potentially much easier and cheaper access than that
usually found in illicit drug markets in the EU. On the
internet, prices of GBL vary between 9 cents and 2
euros for a 1-gram dose. 
Accidental overdoses that occur in recreational
nightlife settings account for a substantial proportion
of the overall drug related emergencies that require
emergency ambulance or hospital services in a
number of European cities.
Media coverage of 'drink spiking' with GHB —
particularly cases of 'drink spiking' to facilitate
sexual assault (often referred to as 'date rape') —
has brought GHB into the spotlight. However,
forensic evidence points to the more common
presence of alcohol in cases of reported sexual
assault. Evidence for this type of crime is notoriously
difficult to obtain and true incidence may be higher
than identified due to non- or delayed reporting.
Responses to the use of GHB commonly target
nightlife settings and usually consist of training club
staff and disseminating information about the risks of
using GHB. Such prevention often takes place in
conjunction with other interventions related to 'club
drugs' and use of alcohol and drug combinations.
On the internet a wide range of information sources
on GHB/GBL exist, generally targeting drug users,
recreational drug users or users attending electronic
dance music events.
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Introduction
GHB is a compound which occurs naturally in
the body, but is also a medicinal product and a
recreational drug. Non-medical use of GHB is
reported to have begun in the 1980s by body
builders. Use of GHB surfaced on the
recreational nightlife scene in some parts of
Europe, USA and Australia during the 1990s,
specifically in night clubs where many other
drugs were being commonly used. Concerns
quickly arose about the health risks associated
with its use. In particular, anxieties arose about
the potential for surreptitiously adding GHB to
drinks (commonly referred to as 'drink spiking')
to facilitate sexual assault. 
At the EU level, GHB has been under
surveillance since 2000, when the Horizontal
working party on drugs of the European Council
requested a risk assessment to be carried out on
GHB under the terms of the 1997 Joint action on
new synthetic drugs (EMCDDA, 2002). On the
basis of the resulting risk assessment report, the
Council requested the EMCDDA and Europol to
'actively' monitor GHB. In March 2001, GHB
(shown as gamma-hydroxybutyric acid) was
added to Schedule IV of the 1971 UN
Convention on Psychotropic Substances.
Therefore all EU Member States were bound to
control it under their legislation addressing
psychotropic substances. 
There are no known reported industrial uses of
GHB and new controls rapidly curtailed the
previously open sale of GHB. However,
concerns are increasing about the direct
consumption of GHB's precursor chemicals,
gamma-butyrolactone (GBL) and 1,4-butanediol
(1,4-BD). These are rapidly converted to GHB
when ingested, yet are widely used in the
chemical industry and are commercially
available. Furthermore, GHB can be easily
manufactured from GBL and 1,4-BD. In view of concerns about the diversion of GHB from the
domestic distribution channel and illicit trade of GBL, some Member States — Italy, Latvia and
Sweden — have chosen to control one or both precursors under drug control or equivalent
legislation (EMCDDA, 2007b). 
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About the E-POD project 
This paper is part of a series of EMCDDA E-POD
case studies. Each E-POD case study provides
practical knowledge to help to build a better
European understanding of emerging drug trends,
and to develop optimal responses to them.
GHB/GBL has been selected as the focus for this
study based on the following criteria: there is a lack
of routine data about prevalence of GHB use in the
EU; there are potentially severe health risks
associated with its consumption and there is a
potential for its use to spread. In addition, there
have been anecdotal reports about an increase in
hospital emergency admissions related to the illicit
use of a precursor chemical to GHB, GBL.
Main sources of information for the case study on
GHB are:
• EMCDDA reporting form (Detecting, tracking and
understanding emerging trends, between July
2005 and October 2005) 
• Early Warning System reports
• National Reitox reports
• EMCDDA risk assessment report
• EMCDDA drug profiles
• ESPAD School Survey Project
• Scientific articles published in peer reviewed
journals
• Published literature 
• Forensic science bulletins
• Official governmental and international
organisations documents 
• Grey literature 
• Newspaper and magazine media articles
• Internet websites and discussion groups
• Personal communication with key informants
Although GBL and 1,4-BD are not included in the
Tables of the 1988 UN Convention against Illicit
Traffic in Narcotic Drugs and Psychotropic
Substances, the European Community and the
Member States have taken additional voluntary
measures to prevent their diversion. These
include guidance for operators to be vigilant
when placing these substances onto the
international market. Discussions about possible
further controls of the two precursors are in
progress in the UK. 
Description
GHB is an abbreviation for both gamma-
hydroxybutyric acid (protonated form) and
gamma-hydroxybutyrate (deprotonated form of
the carboxylic acid moiety). GHB was first
synthesised in 1960 (Laborit, 1964), but was
later discovered to be an endogenous compound
present at very low levels in the body (Bessman
and Fishbein, 1963). Importantly, GHB is also a
product of post-mortem decomposition.
GHB can form salts (e.g. sodium and potassium
salts), which are soluble in water and alcohol. It
is colourless and easily mixes in aqueous
solutions; however, a salty taste may be
noticeable (Ward et al., 1998).
Recreationally, GHB is usually obtained in the form of a liquid formulation. Rarely, it is also
encountered as a powder, either loose or in capsules. Prior to sale or consumption the powder
(usually GHB sodium salt) is typically mixed with water and the route of administration is usually
oral. 1ml of such liquid usually contains approximately 1g GHB, although there may be variances
in the GHB concentrations of such solutions.
GHB is a central nervous system (CNS) depressant but its specific action is not fully understood. However,
it is believed that GHB binds to GABAB and GHB-specific receptors (Benavides et al., 1982 and Maitre
et al., 1990) that lead to an increase in dopamine in the brain. There may also be an accompanied
increase in the release of endogenous opioids, for example, dynorphin (Hechler et al., 1991). 
At low doses, GHB effects are similar to those of alcohol. Sought after effects from ingestion of GHB
are euphoria, relaxation, reduced inhibition and sedation depending on the dose taken. Non-
medically, GHB is used for its relaxant and euphoric effects, to enhance bodybuilding, to induce
sleep and as an alcohol/drug substitute (self-medicating insomnia, depression and alcohol
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Medical use of GHB
Since the 1960s GHB has undergone various pre-
clinical and clinical trials and has been evaluated
for a range of potential therapeutic uses in
obstetrics, anaesthesia, alcohol/opiate withdrawal
and treatment of narcolepsy and cataplexy.
Furthermore, some reports have suggested anti-
depressant effects of GHB as well as sex
enhancing effects in humans.
The international non-proprietary name of GHB is
sodium oxybate. Pharmaceutically, it is presented
as sodium gamma-hydroxybutyrate in liquid form.
It was originally evaluated and is used as an
anaesthetic, particularly in France and Germany
as Gamma OH™ and Somsanit™, respectively. It
has also been assessed in the treatment of
narcolepsy and associated disorders such as
cataplexy (1), in addition to its use as an aid to
opiate and alcohol withdrawal as Alcover™ in
Austria and Italy. In June 2005, the European
Medicines Agency (EMEA) recommended granting
a marketing authorisation for the medicinal
product Xyrem®, where the active substance is
sodium oxybate (500 mg/ml), to treat adults who
have narcolepsy with cataplexy (EMEA, 2005).
Consequently, in October 2005 the European
Commission granted a marketing authorisation for
Xyrem valid throughout the European Union.
Xyrem can only be obtained with a special
prescription; it is given at a dose of 4.5 to 9g per
day in two equally divided doses (EMEA, 2005).
GHB is not authorised for veterinary use.
(1) Narcolepsy is a sleep disorder that causes excessive daytime sleepiness; cataplexy is a symptom of narcolepsy
involving sudden muscle weakness in response to an emotional reaction.
dependence) for sexual relaxation and
disinhibition.
If pharmaceutical-grade GHB (i.e. >99 % purity)
cannot be obtained, illicit GHB can be easily
synthesized from a chemical precursor, gamma-
butyrolactone (GBL) by changing the pH with
addition of an alkali (e.g. sodium hydroxide).
There are dangers associated with this,
particularly as the reaction is exothermic (2) and
GBL is flammable. Commercially and widely
available as a solvent, GBL is also a metabolic
precursor, which when ingested can be
converted in the body to GHB. The other
precursor, 1,4-BD, is also rapidly converted in
the body to GHB. GBL and 1,4-BD produce
effects that are identical to those of GHB
(ACMD, 2002). It is important to note that in vivo
1,4-BD is converted into GHB by alcohol
dehydrogenase (González and Nutt, 2005),
therefore its metabolism may be affected by
alcohol co-ingestion. Preparations of both
precursors may be ingested by users,
consequently information about GHB that is
based on self-reports of users (in the absence of
forensic or toxicological analysis) may relate to
direct use of a precursor chemical (most likely
GBL) rather than GHB.
Prevalence and use patterns
Most information about the prevalence of GHB use is derived from surveys which ask respondents
about their drug use. Whilst respondents may report that they have used GHB, they may in fact have
used one of its precursor chemicals. There have been reports of the precursor chemical (GBL) being
sold as GHB which are based on chemical analyses of liquid drugs seized from individuals
attending nightclub venues in London (Wood et al., 2007). Hence, when referring to prevalence and
patterns of use, the term GHB/GBL may include known or unknown use of GBL or 1,4-BD,
particularly in surveys conducted after GHB was placed under drug control and when it began to
be substituted by GBL. 
On the basis of the limited information available, use of GHB/GBL is, generally, low in the EU but
there is evidence of some sub-populations, settings and geographical areas where it is commonly
used, such as in gay nightclubs. 
In 2003, national school survey data collected in 25 Member States plus Norway, Croatia and
Turkey indicated that GHB/GBL has been tried by a very small proportion of 15-16 year olds
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Methods
Information about GHB that is based on self-reports
of users (in the absence of forensic analysis) may
relate to direct use of a precursor chemical (most
likely GBL) rather than GHB.The relatively recent
introduction of GHB/GBL into the illicit drug market
means that information on its use is not within the
routine reporting scope of many general population
surveys. However, ESPAD and some other
representative school student surveys that were
developed during the 1990s include questions about
the use of GHB/GBL. Prevalence estimates of
GHB/GBL use reported in these surveys are very low
and because they are usually based on a very small
number of students they can only be indicative. In
addition to school surveys, information about the
prevalence and patterns of GHB/GBL use is derived
from a range of non-probability surveys conducted in
dance music settings and other surveys that target
individuals with a prior interest in recreational drugs.
These non-probability surveys (conducted in a limited
number of countries) almost always show higher
prevalence estimates of illegal drug use than those
found in general population surveys. They cannot,
therefore, be regarded as representative in any
statistical sense, and drawing comparisons between
different countries or over time based on these
surveys must be done with caution. 
(2) Exothermic reaction, i.e. which releases energy (heat). 
(somewhere between 0.5 % and 1.4 %) in 12
EU countries. These school surveys show that the
students generally perceive GHB/GBL to be
considerably less available than cannabis,
despite current concerns about the ease of
access to GHB/GBL. With regard to risk
perceptions, the majority of students view the
risks associated with trying GHB/GBL to be as
low, or even lower, than the risks of trying
cannabis in more than half the countries
surveyed (Hibell et al., 2005). 
Surveys conducted in dance music settings and
other targeted surveys report prevalence
estimates for ever in lifetime use of GHB/GBL that range from 3 % to 19 %. For example, a large
UK Independent Drug Monitoring Unit (IDMU) survey, using anonymous questionnaires distributed
at popular music festivals and similar outdoor events between 1999 and 2002, reported that
approximately 3.4 % of over 8,000 respondents had ever used GHB/GBL (Atha and Davis, 2003).
An Austrian study of 225 young people attending raves in Vienna in 2002 reported that 12.6 %
had ever used GHB/GBL (EMCDDA Reitox Early Warning System Report). A survey of 408 pub-
goers in Amsterdam conducted in 2005 reported lifetime prevalence of 10 %. However, evidence
suggests a rather niche market for GHB/GBL where use is concentrated in very specific
subpopulations. Among respondents sampled in 'gay' Amsterdam bars prevalence estimates for
GHB/GBL use rose to 17.5 % and in the city's 'hip' bars 19 % compared to less than 5 % among
respondents in the more mainstream or student pubs (Nabben, Benschop, Korf, 2006). A UK
clubber's magazine survey, based on a self-selected sample of readers of Mixmag in 2004
represents a population that generally reports higher than average prevalence estimates for drug
use, reported lifetime prevalence estimates of 18.1 % for use of GHB/GBL. Prevalence drops to less
than 3 % in all estimates for last month use (Mitcheson, 2007: personal communication). A UK
survey shows that the peak age for first trying GHB/GBL is in young adulthood and not in the
teenage years which are associated with first trying cannabis and other drugs. This suggests that
most GHB/GBL users will have tried many other drugs before experimenting with GHB/GBL (Atha
and Davis, 2003). It should be noted that data sources located in recreational dance music settings
will inevitably under-represent those who generally take GHB/GBL in more private settings for the
purposes of relaxation and recreation or to self-medicate in relation to sleep, alcohol or other
substance abuse problems.
Two European surveys provide a more profound understanding about the effects of GHB/GBL and
about the users themselves and the context of their use. These surveys have been conducted among
targeted population groups that use or have used GHB/GBL. The first was a Dutch survey conducted
in 2001 among 72 GHB/GBL users (3). It reported that three quarters of the respondents had taken
GHB/GBL at least once a month in the past year and half of these had taken it at least once a week.
Most took GHB/GBL in combination with other substances (Korf et al., 2002). The second survey,
conducted in the UK in 2006, was an internet survey of 189 GHB/GBL users (4). This survey
reported that a third of the 189 users had taken GHB/GBL during the last month and two thirds
reported mixing GHB/GBL with other drugs (Sumnall et al., 2007). 
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(3) GHB users defined as having taken GHB 5 times or more in their lifetime and at least once in the past year.
(4) GHB users defined as having taken GHB at least once in their lifetime. The majority of internet respondents (129)
resided in the UK.
Methods
During the early stages of an emerging drug trend,
prevalence estimates are inevitably very low and
confined to specific geographical areas and sub
population groups. Data are limited and usually lack
the methodological requirements needed for making
robust comparisons over time. Therefore methods to
assess developments in a new drug trend must
invariably tap into a wide range of different sources
rather than rely on the key indicators commonly used
for assessing changes in the more common and well
established drug trends.
Trends
There are a small number of surveys that shed light on the diffusion of GHB/GBL use and its
emergence as a new drug trend. A UK clubbing magazine survey which was conducted annually
between 1999 and 2003 reported that ever in lifetime use of GHB/GBL increased over this 5-year
period (Mitcheson, 2007: personal communication). Similarly, the Independent Drug Monitoring
Unit (IDMU) survey, which has been conducting large scale surveys of drug use in the UK since
1997, reported a small but steady year on year rise in prevalence of GHB/GBL use up to 2000
and then a falling trend. However, it should be noted that these surveys cannot be regarded as
representative in any statistical sense. Respondents are often self-nominated and comparability
between samples and over time is usually poor. So any conclusions about trends must be drawn with
caution. However findings from the IDMU survey (Figure 1) illustrate that the trend in GHB/GBL use
is a relatively new phenomenon in the UK. In a sample of 172 GHB/GBL users, only a few
individuals reported, retrospectively, that they had first used GHB/GBL prior to 1994 and even
fewer prior to 1990 (Atha and Davis, 2003).
Figure 1: Year of first GHB use in the UK IDMU survey (Atha and Davis, 2003)
The IDMU survey also reported a relatively widespread of initiation ages for use of GHB/GBL (Figure 2).
This shows that a number of people in their thirties and forties are trying it for the first time, which is
also consistent with the relatively recent arrival of the substance onto the market (Atha and Davis, 2003). 
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Source: Atha, M. and Davis, S. (2003), ‘Gamma hydroxybutyrate usage, effects and UK prices’, results 
from 1999—2002 IDMU surveys.
Notes: The peak in reported year of first use is consistent with the relatively recent arrival of GHB. Few 
individuals had used the drug prior to 1994 and very few prior to 1990. Note that there is a falling trend 
since 2000.
Figure 2: Age of first GHB/GBL use in the UK IDMU survey (Atha and Davis, 2003)
The annual Amsterdam drug monitoring system (5) reported a modest upward trend in the use of
GHB/GBL around 2000 but by 2002 the spread seemed to have halted. However the 2005 report
notes that use of GHB/GBL may be relatively high among some small and specific sub-populations
(Nabben, Benschop, Korf, 2006). In Germany, the Federal Office of Criminal Investigation (BKA)
reported some diffusion in the consumption of GHB/GBL during this period but no prevalence data
was provided (EWS report Germany, 2003). 
The number of individuals who made contacts with drug help lines with questions or seeking help
about GHB/GBL (by telephone, e-mail and internet chat rooms) have been reported to have
increased in 6 countries in recent years, however this may simply reflect increased concern
generated by media attention rather than concrete increases in prevalence (European Foundation of
Drugs Helplines, 2004–2006). 
Context of use
Most individuals who use GHB/GBL are likely to have tried other drugs before experimenting with
GHB/GBL. This, together with the relatively delayed age at which individuals first use GHB/GBL,
suggests that it is not a substance commonly used by naïve drug users (Sumnall et al., 2007; Atha
and Davis, 2003; Wood et al., 2007). Furthermore, the two main surveys conducted among users
show that GHB/GBL is commonly used in combination with other substances, particularly cannabis,
alcohol and ecstasy (Sumnall et al., 2007; Korf et al., 2002). However it should be noted that
anecdotal information from London suggests that recently some individuals in club settings are using
GHB/GBL alone. Such single substance use may be a result of information campaigns conducted in
GHB and its precursor GBL: an emerging trend case studyEMCDDA thematic papers
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(5) Antenna Amsterdam is a multi-method monitoring system aiming to identify and interpret new trends and
developments in legal and illicit drugs use and gambling among young people in Amsterdam, and to update and
improve drug prevention.
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Source: Atha, M. and Davis, S. (2003), ‘Gamma hydroxy butyrate usage, effects and UK prices’, results 
from 1999-2002 IDMU surveys.
Notes: GHB is not normally a drug used by naïve drug users. Most users will have tried many other drugs 
before experimenting with GHB. The peak ages of initiation are in young adulthood.
the area about the risks of combining GHB/GBL with alcohol and other drugs. However, it may also
reflect informal controls exerted by individuals in mainstream society who wish to avoid the
debilitating hangover effects associated with drug and alcohol combinations that affect daily
functioning.
Evidence suggests that GHB/GBL is probably used in private settings as often, or more often, as in
public nightlife settings. The UK survey of GHB/GBL users reported that GHB/GBL — unlike ecstasy
and other stimulant drugs — is used in private home settings more than in nightlife settings (67 %
and 26 % respectively) (Sumnall et al., 2007), while the Dutch survey reported equal numbers in
each setting. In the Dutch survey GHB/GBL consumption in private homes was usually in the context
of a social event or in the presence of friends or acquaintances (Korf et al., 2002). It has been noted
that individuals who commonly took GHB/GBL in club settings were more likely to report problems
associated with use than those who usually consumed it at home (Sumnall et al., 2007). The rapid
and often unpredictable sedative effects of GHB/GBL pose a greater health risk in a crowded
nightclub than they might in the relative security and comfort of a private home.  Despite security
searches to limit drug use in nightlife venues there are reports that in London GHB/GBL is regularly
smuggled into clubs mixed with water in miniature plastic bottles, condoms and balloons (Druglink
January/February 2007). 
The reported lack of hangover, or other sub-acute, effects may contribute to the relatively high
proportion of users (one third) in the Dutch study who had driven a car after taking GHB/GBL and
others had been passengers in cars driven by someone who had taken it (Korf et al., 2002).
While GHB/GBL appears to be holding, or gaining, ground in some specific populations and
geographical locations, the more mainstream Independent Monitoring Unit (IDMU) UK survey,
reported that respondents gave GHB/GBL an average positive rating of only 2.11 on a scale of 0
to 10, which is much lower than the rating given to other drugs. Furthermore, the overall rating in
2002 was significantly lower than in previous years. In both the UK and the Netherlands the sound
of critical voices in some nightlife circles has been heard regarding the incidence of vomiting and
sudden collapses, which reflect negatively on a club. Researchers there have suggested that negative
reports and the decline in positive rating may also reflect growing publicity about the use of
GHB/GBL for the purpose of sexual assault (Atha and Davis, 2003; Korf et al., 2002). 
GHB and 'drink spiking'(6)
Media coverage of 'drink spiking' with GHB, particularly cases of 'drink spiking' to facilitate sexual
assault (7), has brought GHB into the spotlight. However, forensic evidence points to the more
common presence of alcohol in cases of reported sexual assault. Evidence for this type of crime is
notoriously difficult to obtain and true incidence may be higher than identified due to non-, or
delayed, reporting. In cases of drink 'spiking' that are not reported immediately, the narrow time
window allowed for detecting GHB/GBL in body fluids limits the possibility of establishing evidence.
A number of forensic studies have been conducted in France and the UK since 2000 to investigate
cases of sexual assault which were allegedly facilitated by covert administration of a drug. However,
these have failed to find strong evidence of GHB/GBL use for this purpose. These studies have
revealed that high concentrations of alcohol use and also prescription benzodiazepine drugs are
much more commonly associated with cases of alleged sexual assault than GHB (EMCDDA, 
2008; Scott-Ham and Burton, 2005; Puri, 2007; Hurley et al., 2006; Hughes et al., 2007).
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(6) Covertly adding a drug to a drink usually to incapacitate a potential victim or for entertainment
(7) Often reported in the media as 'date rape'
Market and availability
User terms
The most commonly used abbreviation for the substance are 'GHB' or 'G', but GHB is also widely
referred to as 'liquid X', 'liquid E', 'liquid ecstasy'. The inclusion of references to ecstasy portrays
GHB as having disinhibiting and social effects on a par with MDMA, despite the fact that the two
drugs are chemically very different.
Other market user terms refer to other effects of GHB. The term 'growth hormone booster' relates to
its growth hormone promoting effects, 'woman Viagra' to its libido-enhancing effects. Its relaxing
properties are expressed through 'natural sleep 500', 'organic quaalude' or 'oxy sleep'. With
reference to its use in the context of drug facilitated sexual assault it is commonly referred to as
'grievous bodily harm', 'k.o-Tropfen' (knock out drops) or 'easy lay', 'drogues du viol' (French for
'date rape drug'). Other terms for GHB include 'biberones' (Spanish for 'baby´s bottle'), 'oro
bebible' (Spanish for 'drinkable gold) (8), 'fantasy', 'cherry meth', 'scoop', 'Georgia home boy'. The
terms 'soap' and 'salty water' are probably a reference to the reportedly salty taste of GHB. 
Since the sale of GHB was controlled under drug laws in all Member States, information suggests
that there has been an increase in use of the precursor chemical GBL. User market terms for gamma-
butyrolactone (GBL) include: 'GBL', 'paint stripper', 'serenity 2', 'gamma G', 'blue nitro', 'revivarant',
'renewtrient', 'revitalize plus' or 'weight belt cleaner'. 'Paint stripper' is a reference to the use of GBL
as a solvent found in industrial cleaners and superglue removers. 
Internet information and sales
The internet is an increasingly important platform for users, retailers and lobby groups, as well as
drug demand reduction organisations and professionals, to exercise influence and disseminate
information. The amount of information on GHB/GBL published on the internet is relatively small
compared to information on other illegal drugs. For example in a UK drugs forum, the proportion of
posted messages in a sub-forum on 'GHB' constitutes approximately 3 % of the total posted
messages compared to the sub forum on cannabis, opium/opiates and cocaine/crack which
account for more than 50 % (9). Despite the relatively low number of messages posted on 'GHB',
analysis of the type of information exchanged via forums and retailer sites provides important insight
into patterns of use and acquisition opportunities. 
In order to obtain a snapshot of the type of information available on GHB/GBL — including the
number and type of retailers selling GHB/GBL — direct observation of users postings in forums or
chat-room settings — a systematic search via the search engine GoogleTM (http://www.google.com)
using advanced search strategies was conducted in February 2007. The search used key words in
Dutch, English, French, German, Hungarian, Polish and Spanish. Key words were selected to
identify the sale of GHB/GBL, information sites, as well as forums where discussions and information
exchange take place. Out of all the hits that were listed, the first 100 for each key word were
analysed.
GHB and its precursor GBL: an emerging trend case studyEMCDDA thematic papers
13
(8) http://www.fad.es/Sustancias?id_nodo=65&tipo=0&accion=1&sustancia=13 (accessed October 2007)
(9) http://www.drugs-forum.co.uk/forum/index.php, accessed May 2007
Table 1: Overview of the EMCDDA's internet search and findings 
Sales of GHB and GBL
The EMCDDA risk assessment in 2000 stated that GHB was being distributed through retail outlets
and over the internet. By 2007 the situation had changed. Following its inclusion in the UN
convention, GHB is now bound to be controlled under legislation by all EU Member States.
Accordingly no internet sites with EU country code domains (e.g. .fr, .de, .es) or other indications of
being EU-based (contact address) are allowed to
or were identified as selling GHB. 
On the other hand, because the precursor
chemical GBL is not controlled in many Member
States there are online chemical suppliers that
sell GBL. These chemical suppliers market GBL as
cleaning solvents, multi-purpose removers or
chrome polish and wheel cleaners. A total of 15
chemical suppliers that sell 99.9 % pure GBL
were identified located in the UK, Germany, the
Netherlands and Poland. All except three
suppliers provided health warnings. In 2007 the
internet was facilitating the sale of GBL and so in
2007 there was widespread distribution from
overseas even if restrictions were imposed in the
EU. Prices of GBL vary between 24 and 59 euros
per 250 ml, which equates to around 9 cents to
2 euros for a recreational dose (1ml). GHB is
easily manufactured by adding aqueous sodium
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Methods
Information from internet sources is highly relevant
for detecting, tracking and understanding new drug
trends. The internet offers direct access to the drug
users world via online forums and chat rooms. It
provides information about: the working methods of
online retailers; the way that they respond to users'
demands, changes in the law and other supply
issues. However, the nature of internet sources
presents challenges in the research field to develop
standardised and comparable methods for searching
the internet and assessing the validity of the
information. Methods are needed to identify and
describe the evolving features and concepts around
a specific substance such as changes in its content,
appearance, use and distribution over time. The
development of such internet monitoring methods in
the field of drugs has begun but more multi-
disciplinary exchange is necessary to improve and
develop optimal methods.
hydroxide to gamma-butyrolactone (GBL) and recipes for making GHB can be viewed on the
internet. Nine sites providing GHB recipes were identified, but the sale of GHB kits that include all
the necessary ingredients and instructions to produce GHB appear to be rare. Only two sites selling
such kits to customers were identified. It must be noted however, that there may be kits offered
disguised as e.g. computer cleaning solvents or other solvents that were not captured by the internet
search (US Department of Justice, 2002) (10).
Only a few data are available as regards street prices of GHB/GBL. Reports from available data
suggest that prices for 5ml range from 2 to 8 euros. The UK Independent Drug Monitoring Unit
(IDMU) survey, using anonymous questionnaires distributed at popular music festivals and similar
outdoor events between 1999 and 2002, reported for 2002 an average price of 27 euros (GBP
19.50) per bottle of GHB with average bottle sizes of 62.5 ml. The reported average price of 1ml
was 40 euro cents (31 pence). In a Dutch survey among 72 GHB users conducted in 2001, the
price of a vial of GHB containing approximately 5ml fluctuated between 3 and 6 euros (Korf et al.,
2002). In 2006, the average price of GHB samples (5ml) delivered at the Drugs Information and
Monitoring System (DIMS) in the Netherlands was between 2 and 8 euros. DIMS tests drug samples
supplied by consumers and samples confiscated by security staff (Trimbos Institute, 2007).
Forums discussing GHB/GBL
The internet snapshot revealed a total of 85 forums that contained GHB/GBL-related information.
The majority were general drug forums, fitness/bodybuilder forums, gay forums, dance scene forums
and others (women’s forums, students forums etc.). Separate subsections used for the discussion of
GHB/GBL within these forums are however rare (11). A content analysis of all posted messages on 'GHB'
was undertaken for three large drugs forums (12). Approximately 60 % of the posted messages
concerned GBL, which strongly supports other evidence from grey literature and media reports (13)
that GBL is being used in place of GHB. 
Roughly estimated, a third of posted messages are about the effects of GHB/GBL, about 10 %
include discussion and questions about dosage, and another 7 % about the differences between
GHB and GBL as well as how to produce GHB from GBL and the effects of GHB/GBL when used
with other drugs. Online chemical suppliers of GBL provide easy access, and user descriptions of
their purchasing experiences are the subject of another 5 % of posted messages. The image of GHB
as a 'date rape' drug is portrayed in frequent exchanges between forum visitors warning of this
danger. Such internet warnings may themselves provide the oxygen of publicity that can promote
copy cat crime (Sturman, 2000).
Seizures
No Member State has reported information on large-scale production, trafficking and distribution of
GHB. The proportion of reported seizures of GHB in the EU is very small compared to seizures of
other types of synthetic drugs such as amphetamines and MDMA. 
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(10) http://justice.gov/ndic/pubs1/1621/index.htm
(11) http://1001newsgroups.1001annonces.com/lmess.php?name=alt.drugs.ghb&first=1&last=40, http://www.drugs-
forum.co.uk/forum/forumdisplay.php?f=36, accessed September 2007
(12) http://www.drugs-forum.uk, http://www.drogen-forum.com,
http://1001newsgroups.1001annonces.com/lmess.php?name=alt.drugs.ghb&first=1&last=40#, accessed September 2007
(13) BBC, October 2005, http://news.bbc.co.uk/2/hi/uk_news/magazine/4261788.stm,
http://icsouthlondon.icnetwork.co.uk/0100news/0400lambeth/tm_headline=ghb, December 2006, 9.12.2006, Julia
Littmann, www.badische-zeitung.de (http://www.frsw.de/gbl.htm#Zahl%20der%20GBL-
Abhängigen%20nimmt%20in%20Freiburg%20zu), http://www.koeln.de/artikel/Koeln/Zwei-Koelner-sterben-durch-
Partydroge-GBL-31709-1.html, 7.11.2006
Between 2005 and 2006, seizures of GHB were reported in 12 countries including Belgium, Czech
Republic, Denmark, Finland, Estonia, Germany, Hungary, Netherlands, Norway, Poland, Sweden
and the UK (EMCDDA, Reitox National reports, 2005, 2006; EMCDDA Reitox Early Warning
System Reports, 2005, 2006; EMCDDA Reporting form: Detecting, tracking and understanding
emerging trends, 2005).
Reported trends in seizures of GHB are mixed and difficult to interpret due to a lack of data.
Countries reporting an increase in 2005 compared to the previous year are Estonia and Norway.
The largest quantity of seized GHB was reported from Estonia where 11.44 kg of GHB were seized
when an illegal laboratory manufacturing GHB was discovered by the police in 2005 (EMCDDA
Reitox National reports, 2006; EMCDDA Reitox Early Warning System Reports, 2005). 
There is some evidence that GHB is produced locally in illegal laboratories. Between 2003 and
2005, clandestine laboratories were discovered in Belgium, Estonia and Germany (EMCDDA Reitox
National Reports, 2006, 2004). The most recent data on illegal production of GHB was reported
from Norway at the beginning of 2007 when the police detected a 'basement factory' that
produced GHB (EWS system alert, 2007, Norway).
To supplement seizure data, some countries collect and analyse samples of substances collected in
night club or dance music settings. For example, in the UK individuals who attend nightclubs in
specific areas are searched at the door and any drugs that are found are taken and subsequently
analysed. Between August 2006 and January 2007, 418 samples were collected from clubbers in
a London area with a high concentration of gay club venues. Over half of the samples were in liquid
form. Analysis of 225 liquid samples found that 85 (37.8 %) contained GHB and 140 (62.2 %)
contained the precursor chemical GBL. These findings show that GBL has made significant inroads
into the market for GHB, at least in this area of London (Wood et al., 2008). No samples were found
to contain the other precursor chemical 1,4-BD. In addition none of the non-liquid seizures were
found to contain GHB powder.
Due to the importance of GBL for use in the chemical industry there has been resistance to the
reclassification of the precursors under the national legislation. However there are attempts to
minimise diversion to the recreational drugs market. For example Sweden, Italy and Latvia have
chosen to control one or both precursors and discussions about further controls are in progress in
the UK, where all 'large imports' have to specify the 'end user' (Wood et al., 2008). 1,4-BD has
recently been the subject of substantial media attention due to its use in the manufacture of a
Chinese-made toy called Bindeez (Aqua Dots in North America) which allegedly led to several
intoxications of children in North America and other countries. The toy was recalled by the
distributor in November 2007.(14) (15).
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(14) For example, http://www.cnn.com/2007/US/11/08/toy.recall/index.html;
http://www.spiegel.de/wirtschaft/0,1518,516193,00.html, accessed December 2007
(15) Australia, New Zealand, UK
Dose and effects
Pharmacologically, GHB is believed ultimately to increase the levels of dopamine in the brain with
relatively little effect on other neurotransmitter systems. GHB appears to induce some bradycardia
but no effect on blood pressure. An increase in prolactin and growth hormone secretion has also
been observed in humans.
GHB-induced sleep maintains the natural stages of sleep (1-2-3-4-REM) but has been noted to
lengthen stages 3-4 (delta/slow-wave sleep) followed by REM (rapid eye movement) sleep. The
effect of GHB enhanced sleep appears to wear off after 3-4 hours at doses <2-3g. 
GHB toxicity is dose-dependent and can, in varying degrees, result in nausea, vomiting, aggressive
behaviour, ataxia, somnolence, bradycardia, hypothermia, random clonic movements,
hallucinations, amnesia, coma, respiratory depression and apnoea (cessation of breathing). A steep
dose-response curve has been observed where even a small increase in dose can produce serious
toxic effects. Also, adverse interactions can occur with other sedative drugs (e.g. benzodiazepines),
stimulant drugs (e.g. amphetamine) and alcohol. A recent double-blind controlled study, which
compared the clinical effects of sedative-like drugs in twelve male recreational club drug users, found
that GHB induces euphoria, a feeling of wellbeing, pleasurable effects and some stimulant-like
effects. The effects were close to those induced by flunitrazepan and ethanol, although GHB tended
to produce higher euphoric and pleasurable effects (Abanades et al., 2007).
The clinical effects of GHB usually occur 15 minutes after ingestion and can last approximately 3-4
hours (González and Nutt, 2005). GHB is rapidly absorbed, metabolised and eliminated with a
plasma half-life of approximately 20-30 minutes and is undetectable in urine after approximately 12
hours. This has implications for its detection in body fluids. However, in cases of GBL ingestion, it is
suggested that muscle tissue can sequester a large part of the initial GBL dose, thereby delaying
conversion to GHB and prolonging the duration of action (EMCDDA, 2002). 
GHB appears to 'affect different people in different ways'. A euphoric dose for one person could be
a sedative dose for another (Kam et al., 1998). However, it has been generally suggested that a
0.5g dose be taken for relaxation and disinhibition, a 1g dose for euphoric effect and a 2-3g dose
for deep sleep (Ward et al., 1998). Recreational doses of GHB are reported to be around 2.5g or
more, often imprecisely measured as a 'capful of liquid'. Some users however report ingestion of
doses up to 4-5g in a single session (Erowid - accessed November 2007; Korf et al., 2002).
Non-medically, GHB appears to be most commonly used in recreational nightlife settings for its
relaxant, euphoric and disinhibiting effects. It may also be used for its sleep-inducing effects by
people suffering sleep disorders or as an alcohol/drug substitute by those self-medicating symptoms
of depression, or alcohol/drug dependence. It has also been used by bodybuilders who exploit the
possible growth hormone promoting properties of GHB in their attempts to increase muscle mass. In
the past, the potential anti-ageing effects of GHB have been used to actively promote sales due to
claimed indirect anti-oxidant properties of the compound (EMCDDA, 2002). Furthermore, GHB has
also been promoted in 'sex shops' as a sexual adjunct to enhance libido and sexual function among
both heterosexuals and homosexuals (Romanelli et al., 2003).
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In addition to the danger of steep dose response, further dangers associated with illicit use of GHB
or its precursors are due to variances in the concentrations of the solutions. When GHB is produced
illicitly from GBL, the purity can vary depending on the reagents used and method of synthesis.
Furthermore, commercially-available domestic or industrial products, which could be used for
synthesis, are not produced for human consumption and invariably contain other potentially toxic
substances, including heavy metals and other organic solvents such as acetone or toluene. Use of
such products as reagents may result in serious toxic effects if the resultant impure product is
consumed (EMCDDA, 2002). 
Negative health consequences
Dependence and tolerance 
Dependence on GHB is a recognised clinical
syndrome evidenced by a withdrawal syndrome
when the drug is abruptly discontinued following
regular or chronic use. There is evidence that
physical dependence may occur in recreational
users and various cases of withdrawal symptoms
on cessation from GHB and its precursors have
been documented (Miotto et al., 2001;
Degenhardt et al., 2002; Craig et al., 2000;
Catalano et al., 2001; Dyer et al., 2001;
McDaniel and Miotto, 2001; Schneir et al.,
2001). However, the clinical features have not
been fully characterised (McDonough et al.,
2004). The withdrawal syndrome appears to be
similar to those from other CNS depressants such
as alcohol, sedatives and hypnotics. Symptoms
include insomnia, anxiety and tremor which
usually resolve themselves within two weeks
(Galloway et al., 1997). There are indications
that in frequent, heavy users these symptoms can
progress to severe delirium (Dyer et al., 2001). 
Tolerance can develop to GHB with chronic use or long-term treatment and cross-tolerance between
GHB and alcohol may exist. A Dutch survey, conducted in 2001, offered some evidence of tolerance
among 72 GHB users who had taken GHB five times or more in their lifetime and at least once in
the past year. Some users admitted they were taking increasing doses in order to match previous
effects (Korf et al., 2002). Some clients who attend drug treatment services may have problems
related to their use of GHB. However drug treatment monitoring systems in EU Member States do
not, at present, report specific figures about such clients.
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Methods
There is an absence of an accurate and comparable
system for recording the number of deaths and non-
fatal emergencies related to the use of GHB and its
precursors. EU Member States rarely report such
cases which may be due to low prevalence of GHB
use for a number of reasons such as low awareness
of the substance or to difficulties in its detection.
When critically assessing cases of GHB related
deaths and non-fatal hospital emergencies, the
following factors should be carefully considered: (a)
the presence of other drugs (particularly, alcohol,
opiates and stimulants); (b) the concentration of
GHB found; and (c) the post mortem presence of
GHB where there has been no evidence of GHB
usage. Often the evidence for GHB or related
product ingestion (e.g. GBL or 1,4-BD) is based on
anecdotal or circumstantial evidence. Therefore, a
detailed analysis and assessment of each case
should be attempted. 
Reports of negative effects by users
Information about negative effects from use of GHB/GBL from the users' perspective is limited to a
few surveys conducted among users and from comments made on internet websites. The negative
effects most commonly mentioned by users of the substance are nausea and vomiting, stomach pain
and sudden collapse or slipping rapidly into deep unrousable sleep. One UK-based internet survey
conducted among 189 users of GHB/GBL reported that the most frequently reported adverse
reaction that required intervention after taking GHB/GBL was deep, unrousable sleep. However, the
location of use was significantly associated with the adverse reactions reported, and those using
GHB/GBL in club settings were more likely to report negative effects than those who used GHB/GBL
at home (Sumnall et al., 2007). The Dutch study of 72 GHB/GBL users reported that the majority
had passed out at least once while on GHB/GBL, and some had done so frequently. In addition, a
high incidence of vomiting and sudden collapses were reported (Korf et al. 2002)
Non-fatal emergencies reported by emergency services
A small number of intoxications and emergencies associated with GHB have been reported from the
late 1990s onwards — albeit unsystematically — via the Reitox Early Warning System in Belgium,
Denmark, Finland, Luxembourg, the Netherlands, Spain, Sweden, UK and Norway. It is, however,
important to note that it is not possible analytically to determine whether GHB clinical presentations
are due to ingestion of GHB or its precursors. Sweden and Norway are the only EU countries which
report yearly national figures of GHB detections in biological samples (blood or urine).
In Sweden, for example, detections in body fluid specimens increased from 24 in 1997 to 367 in
2004, then dropped to 290 in 2005 and increased again to 452 in the first eight months of 2006.
In Norway, the number of GHB detections increased from 4 in 1998 to 37 in 2006. Both countries'
figures, however, do not provide enough contextual information to distinguish between prescribed
medical and illicit use (EWS reports). The Swedish Poisons Information Centre compiles national
data on non-fatal intoxications through an analysis of the discharge summaries sent voluntarily by
hospital emergency rooms, toxicology ambulance services etc. According to these data, the number
of non-fatal GHB related intoxications increased from 87 in 2000 and to 115 in 2004. It should be
noted that a substantial proportion of the recorded non-fatal GHB intoxications — 40 in 2000 and
38 in 2004 — were reported by one hospital in Gothenburg, in what might be described as a
'problem district' in south-west of the country. Although overall numbers were higher in 2004 the
proportion of GHB related cases from this one hospital was less marked than it had been in 2000,
which may signify diffusion of the trend in use to other areas of Sweden (Swedish reporting form to
the EMCDDA on Detecting, tracking and understanding emerging trends, 2005). The helpline of the
Swedish Poisons Information Centre recorded 81 inquires in 2003, 108 in 2004 and 62 in the
period January to September 2005 (Ibid., 2005). It should be noted that data on information
requests to the Poisons Centre do not represent the actual number of acute intoxications and serve
only to reflect perceptions about risk.
In the Netherlands, the Municipal Health Service in Amsterdam reported that the number of non-fatal
hospital emergencies due use of GHB rose from 25 in 2000 to 98 in 2004, but fell again to 76 in
2005. This number in 2005, as in previous years, exceeded the number of medical emergencies
attributed to use of hallucinogenic mushrooms (70 cases), ecstasy (63 cases), amphetamine (3
cases) and LSD (1 case). The proportion of requests for emergency assistance requiring
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transportation to a hospital in Amsterdam was also higher for cases related to the use of GHB than
to the use of other drugs. Proportions varied between 35 % for amphetamine to 75 % for ecstasy
but rose to 84 % for GHB (16). In the Netherlands information requests made to poison centres
concerning GHB, also increased by over 25 % between 2004 and 2005 from 190 to 241 (2006
Reitox national report, Netherlands).
In the UK, one London hospital emergency department — with a catchment area that includes local
club venues which typically, but not exclusively cater for the gay club scene — recorded a total of
158 GHB and GBL presentations in 2006. The vast majority of cases related to self-reported
recreational use of GHB, with five cases of accidental misadventure or deliberate self-poisoning. 34 %
of patients reported that they had ingested GHB or GBL alone, but there were no reports of 1,4-BD
ingestion. 34 % of patients reported combinations with alcohol, 32 % with MDMA, 22 % with
ketamine, 14 % with cocaine and 14 % with amphetamines. It should be noted that whilst most self-
reports referred to consumption of GHB, chemical analysis of samples collected from night clubs in
the same catchment area during the same time period found that over half of the samples contained
GBL rather than GHB. Most of the individuals presenting to the emergency department were males
aged 20 to 34 years. (Wood et al., 2008). Reports from an Edinburgh hospital show that GHB-
related admissions have increased from only 3 in 2000 to 39 in 2006. Although these make up only
a very small proportion of all toxicology admissions, the proportion of those related to GHB has
grown steadily since 2000 (Scottish Poisons Information Bureau, 2007: personal communication).
In Spain, there is evidence of a significant number of GHB-related emergencies occurring in
Spanish club settings. In Barcelona 104 GHB overdoses presented to a public hospital
emergency department during a 15 month study period (2000–2001) representing 3.1 % of all
toxicological emergencies and ranking second among all illicit drugs requiring emergency
consultation. The patient profile for GHB intoxication was defined as mainly young and male, with
90 % presenting at weekends. 73 % had simultaneously consumed alcohol and 86 % had ingested
additional illicit drugs. Decrease of consciousness was the main complaint in all cases (Miro et al.,
2002). In Ibiza, 8 % of all drug related emergencies at the Can Misses hospital in 2005 were
related to GHB (17) .
Deaths related to GHB
Deaths involving GHB or related products may not be identified since GHB is not usually detected
during routine toxicological analysis. Furthermore, deaths involving only GHB are rare since the
pattern of GHB use often involves the use of other drugs such as alcohol, ecstasy etc. The presence
of other psychoactive substances, above all sedatives and depressants, is believed to intensify the
toxic effects of GHB. 
EU Member States rarely report death cases associated with GHB. Altogether, five Member States
and Norway have reported GHB related deaths to the EMCDDA, as follows: Denmark and Italy
(one case each), Finland (two cases), Norway and UK (3 cases each). Many more cases have been
reported from Sweden and other sources in the UK, where specific studies have been carried out
(Reitox National reports 2006).
In Sweden, a study with a specific focus on deaths related to GHB and its precursors found 36
cases in the period 1996 (when one case was recorded) to 2004 (when 9 cases were recorded).
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(16) In all of these cases the link with drug use was established on case history and circumstantial information rather
than no toxicological confirmation. 
(17) http://www.ultimahora.es/ibiza/segunda-ib.dba?-1+1007+416662, accessed November 2007
The majority of the cases were classified as accidental poisoning, together with reports of some
suicides (Steinholtz et al., 2005; quoted through the Swedish Reitox National report, 2005). In the
first ten months of 2005, however, GHB had been detected in 5 cases of death (Swedish reporting
form to the EMCDDA on Detecting, tracking and understanding emerging trends, 2005).
An unpublished UK study — using data from the General Register, the Birmingham Regional
Laboratory for Toxicology and the National Programme on Substance Abuse Deaths at St George's,
University of London — recorded a total of 44 GHB/GBL-related death cases in the period 1995 to
2006. The number of cases appears to have first peaked in 2001–2 and then risen to higher levels
in 2005–6. Of the total 44 cases, 4 involved GBL, mostly in 2005–6, including one case where
GBL was the only substance used. The majority of cases involved the ingestion of at least two other
substances, typically alcohol and/or stimulants. It should be noted there is considerable variability
in the range of GHB/GBL levels at post mortem. Several cases with low levels are being closely
examined to determine if the GHB detected is endogenous in origin. Where the circumstances were
known, the majority of deaths (22 of 38) followed recreational use, often by individuals with a
history of substance use. A small number of cases involved the use of GHB to aid sleep and in one
of these to assist body-building (Corkery, 2007).
Responses in clinical settings 
Typical presentation of GHB overdose patients attending emergency departments are coma,
bradycardia and hypothermia. Various possible reversal/antagonising agents have been tested
against the clinical effects of GHB toxicity, but with little or limited effect. Furthermore, due to the
rapid gastro-intestinal absorption of GHB, gastric lavage and administration of activated charcoal
are of limited use. Treatment of GHB intoxication is therefore largely supportive and intubation with
mechanical ventilation is sometimes used, particularly to protect the airway if the patient is vomiting
(Kam et al., 1998). However, in the majority of cases the patient awakes spontaneously within 1.5
to 3 hours. 
Risk reduction and prevention
Interventions on the internet
A total of 135 web sites were identified that provided prevention or harm reduction information on
GHB/GBL. The majority are drug prevention sites, either generally targeting drug users or, more
specifically targeting recreational drug users, particularly those attending rave and techno events.
Three quarters of information sites were located in the UK, Netherlands, Spain, Germany and
France. The vast majority describe the effects and risks of GHB/GBL. In particular, the websites stress
the risk of overdosing, together with the dangers of mixing alcohol with GHB (Figure 3). About one
third of sites included advice about using GHB safely. This typically includes advice to consume low
doses, not to mix GHB/GBL with other drugs, in particular alcohol and opiates, not to consume
whilst alone, as well as not to consume GHB/GBL if suffering from heart or kidney diseases or
epilepsy.
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Figure 3: Warnings on internet sites about the dangers of mixing GHB with alcohol
Interventions in recreational settings
Interventions for drug prevention and harm reduction in responses to the use of GHB/GBL are most
commonly provided by national or community projects targeting nightlife settings. These usually
consist of training club staff and disseminating information about the risks of using GHB/GBL
(Germany, France, the Netherlands, Austria, United Kingdom). Information typically comprises
warnings about the legal implications of the use of GHB, the dangers of consuming 'GHB ' together
with alcohol, as well as advice on precautions to be taken in nightlife settings to avoid having drinks
'spiked', and measures to be taken in case of severe intoxication and coma. 
Figure 4: Warning label from a UK club about GHB
Prevention activities take a number of forms. For example, in
Paris a 'nightclub charter' was developed by the project
'Fêtez Clairs' signed by nightclubs to reduce drug-taking in
their venues (18). Also in Paris, the project 'les nuits claires' is
a coalition of the city and the Parisian law enforcement
authority, prevention organisations, night clubs and local
radio. Its project consists of training club staff and
information dissemination on GHB/GBL (19). The city
authority in Paris has also funded a poster on the risks of
taking GHB which is displayed in some clubs (Figure 5, left).
Another example of prevention activity is a GHB awareness
campaign led by the local police and a charity in one of the
London boroughs with a large lesbian, gay, bisexual and
transgender communities, and home of some of London's
most popular night clubs (20). In London, a guide for 'Safer
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(18) http://www.fetez-clairs.org/index.php?id=8, accessed January 2008.
(19) Forum Français pour la sécurité urbaine/ French Forum for Urban Safety (2007), http://www.ffsu.org
(20) http://www.tht.org.uk/mediacentre/pressreleases/2004/june/ghbawarenessinitiative.htm, accessed 1 March 2007
Source:
http://www.allthingsorange.com/orange/
Sources: http://www.partypack.de; http://www.drugsinfoteam.nl/
clubbing' about health and safety practice at dance venues recommends the presence of trained
first aid personnel on-site to provide support when a drug-related emergency occurs (London Drug
Policy Forum, 1996). In Germany, a poster by a coalition of health organisations warns of the
dangers of GHB overdose (Figure 5, right) as part of a general safer clubbing programme
(Partypack.de). 
Figure 5: Posters on GHB risks from
France (Paris) and Germany (Cologne)
In the Netherlands, the nationwide Clubs
and Drugs projects provide information on
GHB/GBL to party drug users as well as
training to club and pub staff. There are
also First Aid for Drugs and Alcohol (EHBD)
teams that attend clubs and large events
and respond to GHB-related incidents (21).
In London, incidents involving GHB and
GBL overdoses have prompted some club
owners to initiate the provision of
paramedic backup in night clubs (22). The
managing director of All Things Orange,
the parent company of the Fire nightclub in
Vauxhall´s gay district, stated that the club
highlights the dangers of GHB to its clients in order to avoid any negative ramifications on the club
scene. The reasons he give are explicit in his statement that 'GHB is the main reason that the New
York club scene is in tatters right now and we want to do all we can to eliminate the same thing
happening here in the UK (Druglink, 2005) (23).
Interventions targeted at 'drink spiking'
In response to fears about 'drink spiking', the most common advice offered in nightlife settings is to
be attentive and not to leave drinks unattended. Other practical commercial aids to prevent or detect
'drink spiking', such as plastic stoppers and special glasses have been promoted and marketed in
some countries. Some night clubs in the UK offer plastic 'use once only' stoppers that glow in UV
light. Once inserted into the neck of a bottle, the stopper cannot be easily removed, creating a seal
that helps stop pills and illicit substances being slipped into the drink (24). Another measure to
prevent drink spiking has been the production of conical glasses with a sealed hole at the top where
a straw can be inserted. After filling the glass from underneath, the barman seals it so that the drink
cannot be tampered with until the seal at the top is broken with a straw. However, the efficacy of
some of these measures have been questioned. Campaigns have been criticised for undue emphasis
on 'drug spiking', when forensic evidence points to the more common association of alcohol in cases
of alleged sexual assault or 'date rape' (Puri, 2007; Meyers and Almirall, 2004; Beynon et al.,
2006). The Roofie Foundation was established in the UK in 1997 to provide telephone helpline
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(21) http://www.ehbd-team.nl/, accessed May 2007
(22) http://www.knightlifemedicalservices.co.uk/, accessed May 2007
(23) http://scene-out.com/forums/showthread.php?t=823, accessed December 2007 
(24) http://www.spikey.co.uk/, accessed March 2007
Sources: Paris - http://www.fetez-clairs.org ; Germany -
http://partypack.de; http://www.checkup-koeln.de/
support and counselling for women who reported being victims of drug facilitated sexual assault. This 
was set up in response to concerns about the benzodiazepine Rohypnol being misused for this purpose.
In response to increasing concern about drug-facilitated sexual assault, at the beginning of 2007
the European Parliamentary Assembly made a series of recommendations to Council of Europe
Member States. The measures recommended include: a revision of sexual assault legislation;
development of information campaigns; improved support for victims; better and more standardised
methods for forensic analysis and pressure on pharmaceutical companies to alter products that might
be used for sexual assault and that drugs used to facilitate sexual assault be placed on lists of
controlled drugs (Council of Europe, 2006). 
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Conclusions
Although use of GHB is generally low in the EU, the health costs are relatively high compared with
other drugs. In some European cities, accidental GHB overdoses that occur in recreational nightlife
settings account for a substantial proportion of the overall drug emergencies that require emergency
ambulance or hospital services. Negative effects from using GHB/GBL, such as vomiting and risk
of sudden loss of consciousness may serve as a deterrent to many young people in mainstream nightlife
settings. However, survey evidence suggests that a sub-population of practised users may be able to
limit some of these risks and continue to use GHB/GBL. GHB's low price, easy availability and the ease
with which it can be taken may serve to promote diffusion of the trend. Little is known about the use
of GHB/GBL in private settings and about use among marginal or vulnerable populations that may find
the strong sedative effects of GHB/GBL a cheap and accessible substance.
Possible drivers of the trend
• The internet plays a ubiquitous role in Europe in raising awareness about almost everything,
including GHB and GBL. It provides both advice and sales information about both substances. The
ease with which GBL (and thus GHB) can be acquired allows potentially much easier and cheaper
access than that usually found in illicit drug markets in the EU.
• Other factors more specifically related to the substance itself have contributed to the emergence
of a trend in the use of GHB.
The multi-purpose characteristics of GHB and GBL and their pharmacological effects ensure a very
wide customer base. Potential consumers include: clubbers seeking relaxation and
euphoria; bodybuilders with an interest in increasing muscle mass; people interested in purported
anti-aging remedies or seeking enhanced sexual function. The pharmacological status of GHB as
a prescribed drug may make it attractive for those with sleep and drug or alcohol problems, by
lending legitimacy to acts of self medication for these purposes.
• The similarity of GHB to alcohol with regard to both its effects and its liquid form may in due
course, through its familiarity and convenience, facilitate widespread diffusion.
Barriers to the trend 
• Changes in drug legislation since 2000 appear to have had an immediate impact on the open
sale of GHB and on the volume of Internet sales and promotion. However, there is evidence to
suggest that GHB's precursor GBL is being sold and used as a substitute for GHB. 
• Negative health and social effects such as vomiting, sudden collapse and passing out may, for
many, tip the balance against using GHB, particularly in social settings. These undesirable affects
and deaths in particular appear to have prompted campaigns to limit the use of GHB. Club
owners have clear vested economic interests to ensure the safety of their clients and protect the
reputation of the leisure industry and consequently some are investing in prevention activity. 
• It has also been suggested that the association of GHB with sexual assault that has commonly been
portrayed by the mass media and on the internet may be contributing to its 'negative image' and
thus to limiting diffusion.
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